Skip to content
BREAM/SIGNALS

INSIGHT BANK · 28 LIVING CARDS

Follow a question. See what changes.

Evidence, technologies, people and the next test—connected, but not confused.

Linked entity: Pembrolizumab · Clear

Commercializationv2 · 10.13

Investing in another company's drug to advance your own ↗

Read the background →Investing in another company's drug to advance your ownLatest update →BioNTech: mRNA cancer immunotherapy combination misses PFS endpoint; survival evaluation continues

How are costs, rights and returns shared when another company’s technology enables a treatment?

The partnership and combination-development record now includes BNT113. In HPV16-positive head and neck cancer, the pembrolizumab combination did not establish PFS superiority; assessment of OS, the other prespecified primary endpoint, continues.

  1. PFS result announcedRecorded
  2. Prespecified OS assessmentUnverified
  3. Detailed resultsUnverified
Additional source checked

Added the BNT113 PFS result and continuation of the prespecified OS assessment.

NEXT CHECK

The planned OS analysis, detailed PFS results, and explanations of the population and safety findings.

Evidence: www.astrazeneca.com ↗smmttx.com ↗
Evidence, people & history ↗
Commercializationv1 · 10.24

From testing a patient's cancer to making their treatment ↗

Read article →

At what quality, turnaround time and cost can patient-specific medicines be supplied repeatedly?

The company-reported phase 3 trial found two-year recurrence-free survival of 82.2% versus 70.0% after melanoma surgery. The expanded Tempus collaboration covers specimen collection and transfer, with sequencing subject to regulatory approvals.

  1. Phase 3 results reportedRecorded
  2. Assess regulation and supplyUnverified
  3. Commercial scale and costsUnverified
New question opened

Record phase 3 results and supply roles, and track patient-level manufacturing and delivery conditions.

NEXT CHECK

Regulatory decisions, specimen-to-delivery time, manufacturing success, per-patient costs and indication-specific outcomes.

Evidence: JCO Oncology Advances ↗Tempus ↗
Evidence, people & history ↗
Optional readership measurement

Allow this site to record page views, reading progress, a broad referral source and the ID of a prepared editorial post link? Reading and following cards work without this. Hosting-provider traffic logs are separate. Details & settings